JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes.

Abstract

Little is known about whether type 1 (IFNγ), 2 (IL-4/IL-13), or 3 (IL-17A/IL-22) cytokines affect the susceptibility of keratinocytes (KC) to viruses. These immune pathways predominate in various skin diseases: lupus, atopic dermatitis (AD), and psoriasis, respectively. Janus kinase inhibitors (JAKi) are approved to treat both AD and psoriasis, and are in clinical development for lupus. We evaluated whether these cytokines alter viral susceptibility of KC and determined if this effect is modulated by treatment with JAKi. Viral susceptibility to vaccinia virus (VV) or herpes simplex virus-1 (HSV-1) ± JAKi was assessed in immortalized and primary human KC pretreated with cytokines. Exposure to type 2 (IL-4 + IL-13) or the type 3 (IL-22) cytokines significantly increased KC viral susceptibility. Specifically, there was a peak increase of 12.2 ± 3.1-fold (IL-4 + IL-13) or 7.7 ± 2.8-fold (IL-22) in VV infection as measured by plaque number. Conversely, IFNγ significantly reduced susceptibility to VV (63.1 ± 64.4-fold). The IL-4 + IL-13-induced viral susceptibility was reduced (44 ± 16%) by JAK1 inhibition, while the IL-22-enhanced viral susceptibility was diminished (76 ± 19%) by TYK2 inhibition. IFNγ-mediated resistance to viral infection was reversed by JAK2 inhibition (366 ± 294% increase in infection). Cytokines expressed in AD skin (IL-4, IL-13, IL-22) increase KC viral susceptibility while IFNγ is protective. JAKi that target JAK1 or TYK2 reversed cytokine-enhanced viral susceptibility, while JAK2 inhibition reduced the protective effects of IFNγ.

• Authors: Kimberly A Arnold, Liam F Peterson, Lisa A Beck, Matthew G Brewer
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 11 (May 25 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 37298195 (Publication Type: Journal Article)

Chemical References

• Cytokines
• Interleukin-13
• Interleukin-4
• Janus Kinase Inhibitors

Topics

• Humans
• Cytokines (metabolism)
• Interleukin-13 (pharmacology)
• Interleukin-4 (pharmacology, therapeutic use)
• Keratinocytes (metabolism)
• Psoriasis (drug therapy)
• Dermatitis, Atopic (drug therapy)
• Janus Kinase Inhibitors (pharmacology, therapeutic use)
• Vaccinia virus (physiology)